Shamburg News · 8-K filed Nov 5, 2026, 9:00 AM EST
HCW Biologics Closes Up to $10.0 Million Debt Financing With Streeterville Capital
HCWB · HCW Biologics Inc.
- Financing
- Material agreement
- Reg FD disclosure
- Materiality: high
On November 3, 2026, HCW Biologics entered into a Notes Purchase Agreement with Streeterville Capital, LLC providing for two secured promissory notes totaling $10.2 million in original principal, with a $3.2 million A-1 Note and a $7.0 million B Note. The transaction closed on November 4, 2026, with the lender paying $3.0 million less $30,000 in transaction costs at closing and depositing $7.0 million into a controlled account of a newly formed subsidiary. The A-1 Note bears 8% interest and the B Note 5%, both maturing twenty-four months after issuance, and the notes are secured by a deposit account control agreement, a subsidiary guaranty, and a pledge of the subsidiary's membership interests.
Source: SEC EDGAR, Form 8-K, Items 1.01, 7.01, 8.01, 9.01, accession 0001493152-26-050082.
Written from the filing by Shamburg Markets. Figures are as reported by the company.